{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:04Z","timestamp":1793830444520,"version":"4.6.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2021\/097\/Startup\/13"],"award-info":[{"award-number":["NUHSRO\/2021\/097\/Startup\/13"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Accurate diagnosis and staging are crucial for the management of patients with hepatobiliary malignancies. Here, we investigated the efficacy of Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT in detecting hepatobiliary malignancies and compared the results with <jats:sup>18<\/jats:sup>F-FDG PET\/CT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Participants with hepatobiliary malignancies were prospectively enrolled and underwent paired Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 and <jats:sup>18<\/jats:sup>F-FDG PET\/CT from April 2023 to March 2024. Histopathology and\/or follow-up imaging served as the reference standard. The SUVmax of the primary and metastatic lesions between Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 and <jats:sup>18<\/jats:sup>F-FDG PET\/CT were compared using the Wilcoxon signed-rank test. The association between Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 uptake intensity and immunohistochemical FAP expression was analyzed with Spearman <jats:italic toggle=\"yes\">r<\/jats:italic> correlation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Our cohort comprised of 28 patients with hepatobiliary malignancies, including 12 with hepatocellular carcinoma, 13 with intrahepatic cholangiocarcinoma (ICC), 2 with perihilar cholangiocarcinoma, and 1 with gallbladder carcinoma. Of these 28 patients, 13 underwent PET\/CT for initial staging and 15 for restaging. Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT showed higher sensitivity than <jats:sup>18<\/jats:sup>F-FDG PET\/CT for detecting primary tumors [100% (13\/13) vs 92.3% (12\/13)], lymph node metastases [79.2% (42\/53) vs 54.7% (29\/53)], and bone and visceral metastases [97.6% (164\/168) vs 69.0% (116\/168)]. Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT findings led to upstaging or restaging in 6 of 28 patients compared with the <jats:sup>18<\/jats:sup>F-FDG PET\/CT-based stage. In addition, Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT detected tumor-related obstructive inflammation in 7 patients, while <jats:sup>18<\/jats:sup>F-FDG PET\/CT detected it in only 1 patient (25% vs 3.6%). All these 7 patients suffered from cholangiocarcinomas, including 5 with ICC and 2 with perihilar cholangiocarcinomas. The SUVmax of obstructive inflammation on Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT was significantly lower than that of tumor (median SUVmax, 4.0 vs 8.8; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008). A positive correlation was found between FAPI uptake and FAP expression (<jats:italic toggle=\"yes\">r<\/jats:italic> = 0.730, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In patients with hepatobiliary malignancies, Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT outperformed <jats:sup>18<\/jats:sup>F-FDG PET\/CT in detecting primary tumors and metastatic lesions, resulting in more accurate staging or restaging. In addition, Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 PET\/CT showed good detection efficacy for tumor-related obstructive inflammation, which was only found in cholangiocarcinoma, thus rendering Al<jats:sup>18<\/jats:sup>F-NOTA-FAPI-74 the potential to differentiate ICC from hepatocellular carcinoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005889","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T22:00:23Z","timestamp":1745618423000},"page":"612-622","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Al18F-NOTA-FAPI-74 and 18F-FDG PET\/CT in the Evaluation and Staging of Hepatobiliary Malignancies"],"prefix":"10.1097","volume":"50","author":[{"given":"Guozhu","family":"Hou","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8619-4878","authenticated-orcid":false,"given":"Xin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9158-8433","authenticated-orcid":false,"given":"Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-837X","authenticated-orcid":false,"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology"},{"name":"Theranostics Center of Excellence"},{"name":"Nanomedicine Translational Research Program"},{"name":"Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Department of Chemical and Biomolecular Engineering"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6948-1813","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology"},{"name":"Theranostics Center of Excellence"},{"name":"Nanomedicine Translational Research Program"},{"name":"Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine (PET-CT Center)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250619","first-page":"153","article-title":"Current management of hepatocellular carcinoma","volume":"10","author":"Crissien","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2016.11.012","article-title":"Cholangiocarcinoma","volume":"116","author":"Squadroni","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1445-5994.2001.00015.x","article-title":"Current status of positron emission tomography in oncology","volume":"31","author":"Scott","year":"2001","journal-title":"Intern Med J"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3748\/wjg.v25.i11.1289","article-title":"Emerging role of (18)F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma","volume":"25","author":"Lee","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jso.21811","article-title":"Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer","volume":"103","author":"Kobayashi","year":"2011","journal-title":"J Surg Oncol"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"e20932","DOI":"10.1097\/MD.0000000000020932","article-title":"Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography\/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: a meta-analysis","volume":"99","author":"Huang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.acra.2020.01.026","article-title":"The role of 18F-FDG PET\/MRI in the assessment of primary intrahepatic neoplasms","volume":"28","author":"\u00c7elebi","year":"2021","journal-title":"Acad Radiol"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"(68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41416-020-01172-1","article-title":"The fibrotic and immune microenvironments as targetable drivers of metastasis","volume":"124","author":"Boulter","year":"2021","journal-title":"Br J Cancer"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET\/CT versus MRI and [(18)F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","article-title":"Comparison of the diagnostic efficacy of (68) Ga-FAPI-04 PET\/MR and (18)F-FDG PET\/CT in patients with pancreatic cancer","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study","volume":"48","author":"Shi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1148\/radiol.213118","article-title":"Prospective comparison of (68)Ga-FAPI versus (18)F-FDG PET\/CT for tumor staging in biliary tract cancers","volume":"304","author":"Lan","year":"2022","journal-title":"Radiology"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","article-title":"Superior tumor detection for (68)Ga-FAPI-46 versus (18)F-FDG PET\/CT and conventional CT in patients with cholangiocarcinoma","volume":"64","author":"Pabst","year":"2023","journal-title":"J Nucl Med"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","article-title":"Initial evaluation of [(18)F]FAPI-74 PET for various histopathologically confirmed cancers and benign lesions","volume":"64","author":"Watabe","year":"2023","journal-title":"J Nucl Med"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.123.266329","article-title":"Fibroblast activation protein-targeted PET\/CT with (18)F-fibroblast activation protein inhibitor-74 for Evaluation of gastrointestinal cancer: comparison with (18)F-FDG PET\/CT","volume":"65","author":"Xu","year":"2024","journal-title":"J Nucl Med"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either (18)F-AlF or Cold-Kit (68)Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.rct.0000237811.88251.d7","article-title":"[F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma","volume":"31","author":"Jadvar","year":"2007","journal-title":"J Comput Assist Tomogr"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.gassur.2003.10.003","article-title":"Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma","volume":"8","author":"Anderson","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/jso.21136","article-title":"Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET\/CT","volume":"98","author":"Li","year":"2008","journal-title":"J Surg Oncol"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00259-002-0852-z","article-title":"Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer","volume":"29","author":"Kato","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(00)80248-2","article-title":"Positron emission tomography scanning in the evaluation of hepatocellular carcinoma","volume":"32","author":"Khan","year":"2000","journal-title":"J Hepatol"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1111\/j.1572-0241.1999.01544.x","article-title":"Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma","volume":"94","author":"Trojan","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jgh.12611","article-title":"Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma","volume":"29","author":"Kawamura","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40644-023-00626-y","article-title":"Head-to-head comparison of (18)F-FAPI and (18)F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma","volume":"23","author":"Zhang","year":"2023","journal-title":"Cancer Imaging"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J Gastroenterol"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10120-013-0234-1","article-title":"Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach","volume":"17","author":"Kwon","year":"2014","journal-title":"Gastric Cancer"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1148\/radiol.2020203275","article-title":"Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers","volume":"298","author":"Pang","year":"2021","journal-title":"Radiology"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1148\/radiol.2016151205","article-title":"Small intrahepatic cholangiocarcinoma and hepatocellular carcinoma in cirrhotic livers may share similar enhancement patterns at multiphase dynamic MR imaging","volume":"281","author":"Huang","year":"2016","journal-title":"Radiology"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1148\/rg.283055108","article-title":"Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features","volume":"28","author":"Hanna","year":"2008","journal-title":"Radiographics"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s00330-017-5196-y","article-title":"Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging","volume":"28","author":"Choi","year":"2018","journal-title":"Eur Radiol"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.crad.2012.01.004","article-title":"Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI","volume":"67","author":"Chong","year":"2012","journal-title":"Clin Radiol"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/RLU.0000000000005112","article-title":"68 Ga-FAPI-04 PET\/CT for the evaluation of cholangiocarcinoma: comparison with 18 F-FDG PET\/CT and abdominal 68 Ga-FAPI-04 PET\/MR","volume":"49","author":"Zhang","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:00:52Z","timestamp":1750341652000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005889"}},"subtitle":["A Single-center Prospective Study"],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005889","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"2025-01-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}